| |
 |
July 2010
Why are more trials being done overseas and what does it mean? |
| |
|
June 2010
Do we need, and how will we find, disease modifying drugs? |
| |
|
May 2010
Do we need better tests for cognitive impairment? |
| |
|
April 2010
The best way to prevent AD will turn out to be: |
| |
|
March 2010
What's the role of vascular disease in AD? |
| |
|
January 2010
What method will be routinely used to predict AD risk? |
| |
|
December 2009
Which non-Abeta area should get the most AD research attention? |
| |
|
November 2009
Would you get tested for your ApoE genotype? |
| |
|
October 2009
What role will identification of new AD genes play in development of therapies? |
| |
|
September 2009
Abeta immunotherapy will most likely succeed as |
| |
|
August 2009
Of anti-Abeta therapeutics, what has the best chance of working? |
| |
|
July 2009
If an AD drug were to show promise as a cognition booster in normal people, and side-effects are tolerable, would you take it? |
| |
|
June 2009
After AD, which is the biggest dementia? |
| |
|
May 2009
Better drugs for AD being a ways off, what measure is most likely to help affected families now? |
| |
|
April 2009
Do NIH informed consent guidelines impede research involving people with dementia? |
| |
|
March 2009
What is the biggest threat to the future of AD research? |
| |
|
February 2009
Should the FDA accept higher risk for AD drug trials? (Assuming consent has been obtained.)
|
| |
|
January 2009
When is the right time for people excluded from trials to be allowed access under Compassionate Use? |
| |
|
December 2008
Would a national registry for families with eFAD be helpful? |
| |
|
November 2008
Are you in favor of ICAD going annual? |
| |
|
October 2008
Compared to cancer, why do so few people with AD participate in drug trials? |
| |
|
September 2008
How are you doing in the current funding climate? |
| |
|
August 2008
Has the time come to include people with EOAD in drug trials? |
| |
|
July 2008
For the purpose of designing intervention trials for people with FAD mutation, is a presymptomatic individual a: |
| |
|
June 2008
GINA is now law of the land. Will this |
| |
|
February 2008
Is AD just the extreme end of the spectrum of normal brain aging? |
| |
|
June 2007
Should doctors encourage athletes in impact-prone sports to find out their ApoE genotype? |
| |
|
May 2007
If your parent had autosomal-dominant AD, would you seek predictive genetic testing? |
| |
|
April 2007
Gain – Loss: How important is presenilin for LOAD anyway? |
| |
|
March 2007
What's the AD drug smith to do about the blood-brain barrier? |
| |
|
February 2007
Would you let your son or daughter play football or any sport that involves a high risk of concussion? |
| |
|
January 2007
Does Abeta have a normal function? Must we understand it in order to conquer AD? |
| |
|
June 2006
Do PS1 mutations cause AD by cranking up Abeta? Recent findings cast doubt (see Discussion. ) Your reaction? |
| |
|
April 2006
Cell cycle genes in AD are back in the news (see Live Discussions). You think... |
| |
|
December 2005
What is you favorite research model for AD? Use the Comments
link to supply strain/species details |
| |
|
November 2005
What is the likely role of Abeta in AD? |
| |
|
October 2005
What role do nonneuronal cells play in AD? |
| |
|
September 2005
What's the biggest impediment to AD drug discovery? |
| |
|
August 2005
What's tau got to do with it? |
| |
|
July 2005
Are academic researchers heeding the "bench to bedside" call?
Respond to our poll and find out. |
| |
|
April 2005
Marijuana for AD treatment: Junkie science or worth sniffing out? |
| |
|
March 2005
If a selective COX-2 inhibitor were shown to prevent or slow
down AD, would you take it? |
| |
|
February 2005
Does cerebral amyloid angiopathy (CAA) get enough attention
from AD researchers? Please explain your reply. |
| |
|
January 2005
What's your New Year Resolution re: AD research? |
| |
|
December 2004
Now that holiday season is upon us, would you go on a
restricted calorie diet to reduce the risk of AD? |
| |
|
November 2004
To cure AD, do we need to understand APP and Abeta function? |
| |
|
October 2004
Does gamma-secretase remain an attractive therapeutic target? |
| |
|
July 2004
Synaptic dysfunction seems to be the new favorite therapeutic target for Alzheimer's, but is cell death still relevant? |
| |
|
April 2004
What is the most likely mechanism by which aging contributes to AD pathogenesis? |
| |
|
March 2004
Does Abeta have a function? |
| |
|
February 2004
John Trojanowski asserts that Alzheimer's is a triple proteinopathy, involving Abeta, tau and alpha-synuclein. You.. |
| |
|
January 2004
What New Year Resolutions have you made in hopes of reducing your risk of Alzheimer's? (Dietary modifications were covered in the December poll.) |
| |
|
December 2003
What dietary changes have you adopted to reduce your risk of AD? |
| |
|
September 2003
What is the best explanation of plaques in nondemented individuals? |
| |
|
June 2003
What is the most promising approach for a predictive biomarker for AD? |
| |
|
May 2003
Protein Aggregation: The Common Denominator? |
| |
|
April 2003
A loved one develops AD. Which experimental therapeutic approach would you be most willing to try? |
| |
|
March 2003
What IS AbPP doing? |
| |
|
February 2003
Vaccination approaches: boost or scuttle? |
| |
|
January 2003
Oxidative Stress: Thumbs up or down? |
| |
|
December 2002
What does synaptic plasticity have to do with AD? |
| |
|
November 2002
Might neurogenesis play a role in AD? |
| |
|
October 2002
How do you think ApoE affects AD risk? |
| |
|
September 2002
Where does tau fit into the picture? |
| |
|
August 2002
What is the significance of cell cycle gene re-expression in AD? |
| |
|
July 2002
Is nonfibrillar Ab the key toxic player?
|
| |
|
December 2000
A year has passed since Dale Schenk and his colleagues at Elan Phamaceuticals startled the research community with their Nature paper showing that vaccination with A-beta peptide reduces plaque deposition in PDAPP transgenic mice. Subsequent studies indicate that the vaccine can also prevent several transgenic mouse models of AD from developing deficits in spatial memory. No adverse side-effects have been reported by Elan in human safety trials to date. If the vaccine reaches Phase II clinical trials, the results could provide a conclusive answer to a central question: Is A-beta necessary and sufficient to cause Alzheimer's disease? |
| |
| |
|
June 2000
Recent studies suggest that the gamma-secretase cleavage of APP and Notch proteins within the transmembrane region is dependent on presenilin-1, and indeed, that PS1 may be the long-sought gamma secretase itself. Regarding to the question whether PS1 is gamma secretase, My Opinion: |
| |
|
May 2000
Regarding the question of amyloid (i.e. extracellular, fibrillar, congophilic material) per se and its role in Alzheimer's disease pathogenesis, I believe that: |
| |
|
April 2000
Do you think intracellular A-beta will prove to be more central to the pathogenesis of AD than extracellular A-beta? |
| |
| |
|
January 2000
Do you think beta amyloid will prove to be the primary pathogenic factor in Alzheimer's disease? |
Home
